Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Hoffman-Censits Discusses the Future Treatment of Bladder Cancer

October 26th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Dr. Uzzo Discusses the Role of Surgery in Kidney Cancer

October 26th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the role of surgery in kidney cancer.

Dr. Geynisman Discusses Immunotherapy in RCC

October 23rd 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma.

NICE Rejects Treatments for Bladder and Thyroid Cancer

October 21st 2017

The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).

Steps Being Taken to Turn mRCC Into a Chronic Disease

October 21st 2017

Daniel M. Geynisman, MD, discusses remaining challenges in the landscape of RCC, despite progress with systemic therapies and the pivotal ongoing studies combining immunotherapy and targeted therapy.

Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer

October 20th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Dr. Harrison on the Possibility of Nivolumab Plus Ipilimumab Becoming the New IL-2

October 20th 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).

Dr. Hoffman-Censits Discusses Immunotherapy in Bladder Cancer

October 19th 2017

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.

Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

October 18th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

Dr. Bosse on the Quality of Life With VEGF Plus Radium-223

October 18th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

FDA Grants Priority Review to Frontline Cabozantinib in RCC

October 16th 2017

The FDA has granted a priority review to a supplemental new drug application for cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma.

Dr. Choueiri on the Research With Immunotherapy in RCC

October 14th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

Dr. Inman Discusses the Role of Chemotherapy in Bladder Cancer

October 13th 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the role of chemotherapy in bladder cancer.

Revised Guidelines Helping to Advance Kidney Cancer Care

October 13th 2017

Robert G. Uzzo, MD, discusses recent guidelines that have impacted clinical practice and ongoing biomarker research in the field of kidney cancer.

Dr. Pal on the CheckMate-214 and CABOSUN Studies in RCC

October 13th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope in Duarte, California, discusses the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

Novel Immunotherapy Approaches Moving Through RCC Pipeline

October 12th 2017

Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.

Dr. Lalani on a Study of Neutrophil-Lymphocyte Ratio in RCC

October 10th 2017

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

Dr. Choueiri on the Role of Cabozantinib in RCC

October 10th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer

October 10th 2017

The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.

Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

October 10th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).